SIGA Technologies (OTCMKTS: SIGA) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares SIGA Technologies and Aevi Genomic Medicine’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies $14.99 million 26.06 -$39.69 million ($0.53) -9.34
Aevi Genomic Medicine N/A N/A -$41.90 million ($0.96) -1.23

SIGA Technologies has higher revenue and earnings than Aevi Genomic Medicine. SIGA Technologies is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.7% of SIGA Technologies shares are owned by institutional investors. Comparatively, 16.8% of Aevi Genomic Medicine shares are owned by institutional investors. 4.7% of SIGA Technologies shares are owned by insiders. Comparatively, 15.2% of Aevi Genomic Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares SIGA Technologies and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies -201.85% N/A -23.22%
Aevi Genomic Medicine N/A -163.88% -130.14%

Analyst Recommendations

This is a summary of recent ratings and price targets for SIGA Technologies and Aevi Genomic Medicine, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SIGA Technologies 0 0 0 0 N/A
Aevi Genomic Medicine 0 1 1 0 2.50

Aevi Genomic Medicine has a consensus price target of $4.25, suggesting a potential upside of 260.17%. Given Aevi Genomic Medicine’s higher probable upside, analysts clearly believe Aevi Genomic Medicine is more favorable than SIGA Technologies.

Risk and Volatility

SIGA Technologies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Aevi Genomic Medicine Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.